Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 2, 2007, Pages 141-145

  Cardellini, Marina ^b   Andreozzi, Francesco ^a   Laratta, Emanuela ^a   Marini, Maria Adelaide ^b   Lauro, Renato ^b   Hribal, Marta Letizia ^a   Petricone, Francesco ^a   Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

IFG; IGT; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ITALY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX RATIO; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INTERLEUKIN-6; ITALY; MALE; MIDDLE AGED;

EID: 33847196836     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.679     Document Type: Article

References (22)

1. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
2. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
3. Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute phase proteins but not TNF-ot α or its receptors. Diabetologia 2002; 45: 805-812, DOI: 10. 1007 /s00125-002-0829-2.
4. Temelkova-Kurktschiev T, Henkel E, Koehler C, et al. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45: 151, DOI: 10.1007/s125-002-8256-1.
5. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
6. American diabetes association: diagnosis and classification of diabetes mellitus (position statement). Diabetes Care 2005; 28: S37-S42.
7. The expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
8. Sesti G, Sciacqua A, Cardellini M, et al. Plasma concentration of insulin-like growth factor-I is independently associated with insulin sensitivity in subjects with different degree of glucose tolerance. Diabetes Care 2005; 28: 132-137.
9. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
10. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48: 2197-2203.
11. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes 2000; 49: 975-980.
12. Davies MJ, Raymond NT, Day JL, et al. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000; 17: 433-440, DOI: 10.1046/j.1464-5491.2000.00246.x.
13. Guerrero-Romero F, Rodriguez-Moran M. Impaired glucose tolerance is a more advanced stage of alteration in the glucose metabolism than impaired fasting glucose. J Diabetes Complicat 2001; 15: 34-37, DOI: 10.1016/S1056-8727(01)00150-7.
14. Hanefeld M, Koehler C, Fuecker K, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose. The risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 2003; 26: 868-874.
15. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404.
16. Nakagami T, The DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394, DOI: 10.1007/s0012S-004-1334-6.
17. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745.
18. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-329, DOI: 10.1016/j.cell.2005.11.044.
19. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072, DOI: 10.1161/01. CIR0000034509.14906.AE.
20. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
21. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
22. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.